We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Walkway at the entrance of the Novartis Campus in Basel, Switzerland

Investors Event Calendar

View recent presentations and learn more about upcoming events.

February 02, 2022
Fourth Quarter and Full Year Results 2021 and Annual Report 2021 publication
Basel, Switzerland

Learn More



Doctor prescribing medication in Rwanda

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

Learn More

ESG Updates: Oct 27, 2021 (PDF 0.5 MB) | July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessments Webinars

We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.


Novartis ESG Investor Day 2021

Novartis shared progress on its most material ESG topics.

Watch highlights

Read the press release

Download slide deck (PDF 9.6 MB)




Pulse Updates

December 16, 2021

Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

Read More

September 28, 2021

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Read More


September 03, 2021

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Read More

September 02, 2021

Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee

Read More

Transmission electron microscopic image of an isolate from a case of coronavirus disease (COVID-19)

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter the Information Center

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.


Stay Up-to-Date



Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland